Halozyme Therapeutics (HALO) Tops Q1 EPS by 4c; FY Revenue Guidance Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 128.95 -1.96 (1.5%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.91 | 52 Week High | $18.39 | |||
| Open | $130.50 | 52 Week Low | $6.96 | |||
| Day High | $131.89 | P/E | N/A | |||
| Day Low | $127.52 | EPS | $-0.58 | |||
| Volume | 3,419,416 | |||||
